EXPLORATION AND QUANTIFICATION OF THE DETERMINANTS OF BASELINE HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR PATIENTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Kyriakou, C. [1 ,2 ]
Petrucci, M. [3 ]
Welslau, M. [4 ]
Leleu, X. [5 ]
Vande Broek, I. [6 ]
Bacon, P. [7 ]
Lewis, P. [8 ]
Gilet, H. [9 ]
Arnould, B. [9 ]
Murphy, P. [10 ]
机构：
[1] Northwick Pk Hosp & Clin Res Ctr, London, England
[2] Royal Free Hosp, London, England
[3] Sapienza Univ Rome, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy
[4] Studienzentrum Hamatol, Aschaffenburg, Germany
[5] CHRU Hop Huriez, Lille, France
[6] AZ Nikolaas, St Niklaas, Belgium
[7] Celgene Int Sarl, Boudry, Switzerland
[8] Celgene GmbH, Munich, Germany
[9] MAPI Consultancy, Lyon, France
[10] Beaumont Hosp, Dublin, Ireland
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
B1502
引用
收藏
页码：600 / 600
页数：1
相关论文
共 50 条
  • [21] HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): THE FIRST TRIAL
    Delforge, M.
    Minuk, L.
    Eisenmann, J. C.
    Arnulf, B.
    Canepa, L.
    Fragasso, A.
    Leyvraz, S.
    Langer, C.
    Ezaydi, Y.
    Vogl, D. T.
    Giraldo-Castellano, P.
    Yoon, S. S.
    Martins, A.
    Zarnitsky, C.
    Escoffre-Barbe, M.
    Lemieux, B.
    Proskorovsky, I.
    Monzini, M. Silva
    Ervin-Haynes, A.
    Houck, V.
    Facon, T.
    HAEMATOLOGICA, 2014, 99 : 109 - 110
  • [22] Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis
    Banerjee, Rahul
    Hasegawa, Ken
    Itani, Taha
    Giordana, Monique
    Granados, Enrique
    Rosado, Margrit B.
    Chan, Rebecca J.
    Kostic, Ana
    Kanters, Steve
    Zoratti, Michael J.
    Leleu, Xavier
    BLOOD, 2024, 144 : 4721 - 4722
  • [23] ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ISS STAGE AND ECOG STATUS IN MULTIPLE MYELOMA
    Pashos, C. L.
    Durie, B. G.
    Mehta, J.
    Toomey, K.
    Terebelo, H. R.
    Abonour, R.
    Fonseca, R.
    Gasparetto, C.
    Narang, M.
    Rifkin, R. M.
    Shah, J. J.
    Sullivan, K. A.
    Street, T. K.
    Khan, Z. M.
    VALUE IN HEALTH, 2011, 14 (03) : A175 - A176
  • [24] DREAMM-2: Belantamab mafodotin (belamaf; GSK2857916) effect on disease symptoms and health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM)
    Weisel, K.
    Popat, R.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Voorhees, P.
    Cohen, A.
    Opalinska, J.
    Gutierrez, B.
    Gorsh, B.
    He, Z.
    Eliason, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 103 - 104
  • [25] Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
    Plesner, Torben
    Dimopoulos, Meletios A.
    Oriol, Albert
    San-Miguel, Jesus
    Bahlis, Nizar J.
    Rabin, Neil
    Suzuki, Kenshi
    Yoon, Sung-Soo
    Ben-Yehuda, Dina
    Cook, Gordon
    Goldschmidt, Hartmut
    Grosicki, Sebastian
    Qin, Xiang
    Fastenau, John
    Garvin, Wendy
    Carson, Robin
    Renaud, Thomas
    Gries, Katharine S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) : 132 - 139
  • [26] Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Gries, Katharine S.
    Fastenau, John
    Kampfenkel, Tobias
    Qiu, Yanping
    Amin, Himal
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Assessment of health-related quality of life (HRQoL) in triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial
    Hoffman, James E.
    Bumma, Naresh
    Richter, Joshua Ryan
    Dhodapkar, Madhav V.
    Lee, Hans C.
    Suvannasankha, Attaya
    Zonder, Jeffrey A.
    Maly, Joseph J.
    Shah, Mansi R.
    Baz, Rachid C.
    DeVeaux, Michelle
    Ivanescu, Cristina
    Rodriguez-Lorenc, Karen
    Kroog, Glenn Scott
    Houvras, Yariv J.
    Inocencio, Timothy J.
    Chi, Lei
    Harnett, James
    Ma, Qiufei
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Variation In Health-Related Quality of Life (HRQOL) by ISS Stage and ECOG Status Among Multiple Myeloma Patients.
    Pashos, Chris L.
    Durie, Brian G. M.
    Rifkin, Robert M.
    Shah, Jatin J.
    Street, Thomas K.
    Sullivan, Kristen A.
    Khan, Zeba M.
    BLOOD, 2010, 116 (21) : 1566 - 1567
  • [29] Health-related quality of life in patients with multiple myeloma - does it matter?
    Kvam, Ann Kristin
    Waage, Anders
    HAEMATOLOGICA, 2015, 100 (06) : 704 - 705
  • [30] Health-related quality of life (HRQOL) in Polish epilepsy patients
    Nicpon, KW
    Szaflarski, JP
    Wrobel, E
    Szaflarskil, M
    EPILEPSIA, 2004, 45 : 86 - 86
12345